Recent real-world data from the Israel Ministry of Health found that unvaccinated individuals were 29 times more likely to die due to COVID-19 complications than those who received two doses of the BNT162b2 Pfizer-BioNTech vaccine.
Also, those who were unvaccinated were 44 times more likely to contract symptomatic COVID-19.
The data also suggest that the vaccine prevents the spread of asymptomatic COVID-19 and is 94% effective against symptomatic disease.
Researchers from the U.K. have also published a preprint that suggested that a single dose of the BNT162b2 vaccine provided a 43% risk of hospitalization and a 51% reduction in death risk in individuals 70 or older.
In addition, the BNT162b2 vaccine was 89% effective at least 14 days after the second vaccination. The U.K. study also found that a single dose of the vaccine resulted in an 85% reduction in the risk of death from COVID-19.
The Israeli data came from Jan. 17 to March 6 when the more B.1.1.7 variant was dominant.
Israel has one of the highest vaccination rates in the world.
Filed Under: clinical trials, Drug Discovery, Infectious Disease
